Climb Total Operating Expenses from 2010 to 2025
| CLYM Stock | 1.41 0.10 6.62% |
Total Operating Expenses | First Reported 2020-03-31 | Previous Quarter 10.9 M | Current Value 23 M | Quarterly Volatility 11.8 M |
Check Climb Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Climb Bio's main balance sheet or income statement drivers, such as Selling General Administrative of 13.8 M, Other Operating Expenses of 42.4 M or Research Development of 17 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.39. Climb financial statements analysis is a perfect complement when working with Climb Bio Valuation or Volatility modules.
Climb | Total Operating Expenses | Build AI portfolio with Climb Stock |
Latest Climb Bio's Total Operating Expenses Growth Pattern
Below is the plot of the Total Operating Expenses of Climb Bio over the last few years. It is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. Climb Bio's Total Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Climb Bio's overall financial position and show how it may be relating to other accounts over time.
| Total Operating Expenses | 10 Years Trend |
|
Total Operating Expenses |
| Timeline |
Climb Total Operating Expenses Regression Statistics
| Arithmetic Mean | 21,307,732 | |
| Geometric Mean | 14,112,034 | |
| Coefficient Of Variation | 102.73 | |
| Mean Deviation | 17,375,007 | |
| Median | 7,446,000 | |
| Standard Deviation | 21,890,431 | |
| Sample Variance | 479.2T | |
| Range | 74.6M | |
| R-Value | 0.79 | |
| Mean Square Error | 195.7T | |
| R-Squared | 0.62 | |
| Significance | 0.0003 | |
| Slope | 3,617,088 | |
| Total Sum of Squares | 7187.9T |
Climb Total Operating Expenses History
About Climb Bio Financial Statements
Climb Bio investors utilize fundamental indicators, such as Total Operating Expenses, to predict how Climb Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Operating Expenses | 82 M | 42.4 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Climb Bio Correlation against competitors. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.